Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease
2011 ◽
Vol 34
(8)
◽
pp. 911-922
◽
Keyword(s):
2016 ◽
Vol 10
(2)
◽
pp. 283-291
◽
Keyword(s):
2018 ◽
Vol 18
(3)
◽
pp. 211-216
2017 ◽
Vol 29
(7)
◽
pp. 844-848
◽
Keyword(s):
2008 ◽
Vol 2
(1)
◽
pp. 7-8
2012 ◽
Vol 6
◽
pp. S120
◽
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 13
(7)
◽
pp. 846-855
◽